Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;170(8):1676-705.
doi: 10.1111/bph.12449.

The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors

Affiliations

The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors

Stephen P H Alexander et al. Br J Pharmacol. 2013 Dec.

Abstract

The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.12444/full. Catalytic receptors are one of the seven major pharmacological targets into which the Guide is divided, with the others being G protein-coupled receptors, ligand-gated ion channels, ion channels, nuclear hormone receptors, transporters and enzymes. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. A new landscape format has easy to use tables comparing related targets. It is a condensed version of material contemporary to late 2013, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented in previous Guides to Receptors and Channels. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and the Guide to Receptors and Channels, providing a permanent, citable, point-in-time record that will survive database updates.

PubMed Disclaimer

References

Further reading

    1. Broughton SE. Dhagat U. Hercus TR. Nero TL. Grimbaldeston MA. Bonder CS. Lopez AF. Parker MW. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev. 2013;250:277–302. [PMID:23046136] - PubMed
    1. Chang SH. Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal. 2011;23:1069–1075. [PMID:21130872] - PMC - PubMed
    1. Donnelly RP. Dickensheets H. O'Brien TR. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol. 2011;32:443–450. [PMID:21820962] - PMC - PubMed
    1. George PM. Badiger R. Alazawi W. Foster GR. Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135:44–53. [PMID:22484806] - PubMed
    1. Gibbert K. Schlaak JF. Yang D. Dittmer U. IFN-α subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol. 2013;168:1048–1058. [PMID:23072338] - PMC - PubMed

References

    1. Akeson AL, et al. J Biol Chem. 1996;271:30517–30523. [PMID: 8940020 ] - PubMed
    1. Morokata, et al. Int Immunopharmacol. 2002;2:1693–1702. [PMID: 12469943 ] - PubMed
    1. Tilley JW, et al. Journal of the American Chemical Society. 1997;119:7589–7590.
    1. Klein RD, et al. Nature. 1997;387:717–721. [PMID: 9192898 ] - PubMed
    1. Mologni L, et al. J Mol Endocrinol. 2006;37:199–212. [PMID: 17032739 ] - PubMed

Publication types